Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

GSK confirms positive results from shingles trial in China

August 23, 2023 Research and Development GSK, Infections and infestations, clinical trials, shingles

GSK has announced positive results today from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China. These …
News

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023 Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
News

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023 Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …
News

FDA approves Pfizer’s vaccine for the prevention of RSV in children

August 22, 2023 Research and Development FDA, Paediatrics, Pfizer, RSV

On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory …
News

Recce Pharmaceuticals shares data from phase 1/2 trial for burn wound infection

August 21, 2023 Research and Development Recce Pharmaceuticals, Wound Healing, burn wounds, clinical trial, infection

Recce Pharmaceuticals has announced that it has completed its data analysis for its phase 1/2 clinical trial of Recce 327 …
News
blood-1813410_960_720

Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023 Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
News

FDA approves first ever treatment for rare CHAPLE disease

August 21, 2023 Research and Development CHAPLE disease, FDA, Rare Diseases, rare disease

The US Food and Drug Administration (FDA) has approved Regeneron’s Veopoz (pozelimab), a new treatment for CHAPLE disease for both …
News

FDA approves IMIDEX’s AI-powered device VisiRad XR

August 18, 2023 Research and Development FDA, Radiology, pharma, radiology

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug Administration (FDA) for its artificial …
News

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

August 17, 2023 Research and Development FDA, IND, Immunology, lupus nephritis, pharma

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ Investigational New Drug (IND) application …
News
eye1

Sandoz shares positive results from MYLIGHT phase 3 study

August 16, 2023 Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration

Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …
News
testalize-me-0je8ynv4mis-unsplash

Tempus receives FDA Breakthrough Device Designation for its companion diagnostic test

August 16, 2023 Research and Development Diagnostics, FDA, Tempus, breakthrough device designation, diagnostic

Tempus has announced that the US Food and Drug Administration (FDA) has granted it Breakthrough Device Designation for its HLA-LOH …
News

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

August 14, 2023 Research and Development AI, Draft Guidance, NICE, Oncology, radiotherapy

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine artificial intelligence (AI) technologies which …
News

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023 Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
News

Zumutor’s cancer drug trial cleared by FDA

August 14, 2023 Research and Development Cancer, Oncology, clinical trial, pharmaceutical

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its ZM008 drug for cancer had …
News

FDA accepts Astellas’ sNDA for Cresemba in children

August 11, 2023 Research and Development Astella, FDA, Paediatrics, cresemba

The US Food and Drug Administration (FDA) announced it has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for Cresemba …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026